EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis

Miriam Martínez-Santos, María Ybarra, Maria E Pires, Chiara Ceresoni, Elías Martínez-López, Javier Sancho-Pelluz, Maria Oltra iD, Jorge M Barcia

PLOS One · 2025

DOI: 10.1371/journal.pone.0335434 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS One, 2025. Verfasst von Miriam Martínez-Santos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Escuela de Doctorado Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Circulating MicroRNA, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Instituto de Salud Carlos III, HORIZON EUROPE Marie Sklodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the diagnostic accuracy of circulating miRNAs in distinguishing between different diabetic retinopathy (DR) stages in type 2 diabetes mellitus (T2DM).

Methods

We conducted a systematic review and meta-analysis in accordance with PRISMA-DTA and Cochrane guidelines. The protocol was not registeres and no external funding was received. A comprehensive search was performed in PubMed, CENTRAL, Scopus, Web of Science, ScienceDirect, and ClinicalTrials (up to January 2025) to identify diagnostic test accuracy studies on circulating miRNAs for DR. Eligible studies included three predefined comparisons: healthy controls versus DR (CTL vs DR), T2DM without DR versus DR (T2DM vs DR), and non-proliferative versus proliferative DR (NPDR vs PDR). DR diagnosis was confirmed using fundus fluorescein angiography and/or fundus examination. Two reviewers independently conducted study selection, data extraction, and risk of bias assessment with QUADAS-2; certainty of evidence was assessed using GRADE. Data were synthesized using a bivariate random-effects meta-analysis, with subgroup analyses, meta-regression, and sensitivity analyses to explore heterogeneity. Data were synthesized via a bivariate random-effects meta-analysis, with subgroup analyses, meta-regression, and sensitivity tests to explore heterogeneity.

Results

Sixteen studies (1849 participants; 21 miRNAs) were included. For CTL vs DR (7 studies), pooled sensitivity was 77% (70–82) and specificity 84% (77–89), AUC 0.86 (0.82–0.89). For T2DM vs DR (9 studies), sensitivity was 81% (75–86) and specificity 80% (71–87), AUC 0.88 (0.84–0.91). For NPDR vs PDR (12 studies), sensitivity was 84% (79–87) and specificity 82% (76–88), AUC 0.90 (0.87–0.93). Heterogeneity arose chiefly from sample matrix, normalization strategies and inter-study expression trends. Patient selection posed the greatest bias risk.

Conclusions

Circulating miRNAs exhibit promising diagnostic accuracy for differentiating among various stages of DR. However, future large, prospective studies in diverse populations and standardized pre-analytical protocols are required to confirm and translate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyCirculating MicroRNADiabetes Mellitus, Type 2HumansBiomarkers

Substanzen

Circulating MicroRNABiomarkers

Autor:innen und Institutionen

  • Escuela de Doctorado Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain.
  • Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain.
  • Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain.
  • Department of General and Digestive Surgery, Hospital Universitario Doctor Peset, Valencia, Spain.

ORCID-Profile: Maria Oltra

Förderung

  • Agencia Estatal de Investigación
  • Instituto de Salud Carlos III
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana

Zitieren

APA

Martínez-Santos, M., Ybarra, M., Pires, M. E., Ceresoni, C., Martínez-López, E., Sancho-Pelluz, J., Oltra, M., & Barcia, J. M. (2025). Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis. PLOS One. https://doi.org/10.1371/journal.pone.0335434

Vancouver

Martínez-Santos M, Ybarra M, Pires ME, Ceresoni C, Martínez-López E, Sancho-Pelluz J, et al. Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis. PLOS One. 2025. doi:10.1371/journal.pone.0335434

BibTeX
@article{MartnezSantos2025,
  author = {Martínez-Santos, Miriam and Ybarra, María and Pires, Maria E and Ceresoni, Chiara and Martínez-López, Elías and Sancho-Pelluz, Javier and Oltra, Maria and Barcia, Jorge M},
  title = {Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0335434}
}
Kostenlos starten →